Literature DB >> 24640599

Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation.

Xin Li, Qingwei Jiang, Lina Du, Ying Li, Miao Li.   

Abstract

The aim of the present study was to develop the novel immediate-controlled release (ICR) tablets of isosorbide-5-mononitrate (5-ISMN) composed of an osmotic pump tablet core coated with an immediate-release layer. The novel ICR tablets of 5-ISMN could release drug quickly and continuously through a semi-permeable membrane (SPM) composed of ethylcellulose (EC)/polyethylene glycol (PEG) 4000 and cellulose acetate (CA)/PEG4000. Release tended to decrease with storage time. However, the drug release rates changed little for the SPM composed of EC/PVP K30. The weight loss test also confirmed these results. The major release mechanism was diffusion according to the Higuchi equation. The relative bioavailability of the ICR tablets compared to the reference formulation in the single and multiple dose regiments were 90.9 and 111.2%, respectively. They were both bioequivalent to the reference formulation. In vitro-in vivo correlation (IVIVC) studies demonstrated that the dissolution in vitro simulated the absorption in vivo well. In general, 5-ISMN ICR tablets composed of an osmotic pump tablet core and an immediate-release layer may be promising in providing immediate and constant drug delivery with minimum fluctuations during long storage time.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24640599

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  1 in total

1.  Determination of Isosorbide-5-Mononitrate in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Bioequivalence Study.

Authors:  Yinping Zhou; Aijing Liu; Ranran Jia; Mengyi Wu; Ni Wu; Chunyan Liu; Zhihui Han; Haitang Hu; Hongyun Wang; Qing He
Journal:  J Anal Methods Chem       Date:  2020-07-17       Impact factor: 2.193

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.